Fractionated stereotactic re-irradiation after plaque radiotherapy (brachytherapy) failure in uveal melanoma
Radiotherapy Department, The Greater Poland Cancer Centre, Poznan, Poland
Department of Ophthalmology, Poznan University of Medical Sciences, Poznan, Poland
J Contemp Brachytherapy 2026; 18
Purpose
Local recurrence after ruthenium-106 (106Ru) interventional radiotherapy (IRT) for uveal melanoma remains a therapeutic challenge. This study aimed to evaluate the efficacy and safety of fractionated stereotactic radiotherapy (fSRT) used as a salvage, globe-preserving option after failed IRT.
Material and methods
Patients with locally recurrent uveal melanoma
previously treated with 106Ru
brachytherapy were retrospectively analyzed. All patients underwent
transpupillary thermotherapy as first-line salvage treatment,
followed by fSRT delivered with CyberKnife. Follow-up examinations
were performed every 3-6 months, and inclu-
ded assessment of
visual acuity, intraocular pressure, ophtahlmic examination and liver
ultrasound every 6 months.
Results
Nine patients were identified. The median interval between brachytherapy and recurrence was 15.1 months, and the median follow-up after fSRT was 45.2 months. The majority (78%) of eye globes were salvaged. The most frequent toxicity was cataract (55.6%); no secondary glaucoma or distant metastases were observed.
Conclusions
Salvage treatment with fSRT after 106Ru IRT failure provides excellent local control with acceptable toxicity. This approach represents an effective, non-invasive alternative to enucleation in selected patients with recurrent uveal melanoma.
Keywords
uveal melanoma recurrence, stereotactic radiotherapy, salvage radiotherapy, plaque brachytherapy, CyberKnife
Integrated with
